Results 171 to 180 of about 586,559 (303)
Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse +20 more
wiley +1 more source
Editorial: Biomarkers and precision medicine in myeloid neoplasms. [PDF]
Datta Mitra A.
europepmc +1 more source
This study introduces β‐glucan‐shielded apremilast laden nanomicelles that withstand gastrointestinal degradation, selectively accumulate in inflamed colon tissue, and modulate the microbiota–gut–brain axis. The formulation restores barrier integrity, reduces systemic and neuroinflammation, and improves anxiety‐ and depression‐like behaviors in colitis
Chandrashekhar Jori +10 more
wiley +1 more source
High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model. [PDF]
Briesch H +9 more
europepmc +1 more source
An in situ‐grown BP‐CaO2 nanoplatform supplies coordinated Ca2+, endogenous phosphate, and oxidative stress to convert tumor calcification from a passive endpoint into an active immune‐remodeling process. Widespread hydroxyapatite deposition is visualized by CT, while multi‐omics reveals MCOLN2 as a calcium‐responsive mediator linking biomineralization
Long Liu +11 more
wiley +1 more source
A nanobiohybrid vaccine was designed by constructing a hydrogen‐bonded organic framework coencapsulated with glucose oxidase (GOx) and tumor antigens. This nanobiohybrid vaccine executed a GOx‐catalyzed enzyme reaction that disrupted glucose metabolism and induced redox imbalance in dendritic cells, leading to autophagy‐dependent antigen cross ...
Weidong Wang +5 more
wiley +1 more source
We developed an ultrasound‐controlled biomimetic nanoplatform, mRNA/V@M NPs, to co‐deliver CD74 mRNA and V‐9302 for fibrotic TNBC therapy. CD74 mRNA reprograms myCAFs into antigen‐presenting apCAF cells through the CD74‐MHC II pathway, while V‐9302 induces ICD and activates MHC I‐CD8+ T cell immunity.
Chen Ai +9 more
wiley +1 more source
Secreted protein circuits in the gastrointestinal tumour microenvironment: determinants of immunotherapy response and resistance. [PDF]
Li K, Qian Z, Mao J, Han Y, Leng X.
europepmc +1 more source
Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer +9 more
wiley +1 more source

